Franklin’s Somatic Workflow

TSO 500

Franklin TSO 500 solution is an end-to-end suite of tools that help you improve tumor case analysis by combining AI technology with the richest genetic data available, derived from public annotation, community contributions, and Franklin’s own curated clinical evidence.

Used by top laboratories worldwide

Streamlined DNA and RNA analysis

Automated AMP and ACMG variant classification

Fast-track to report

Join the Franklin community today!

Franklin has been optimized for all of the TruSight Oncology 500 workflows, including the original (TSO 500), high throughput (TSO 500 HT), and the liquid biopsy (TSO 500 ctDNA) assays, supporting each step from raw data to reporting. The platform can easily integrate with existing or new TSO 500 lab workflows, using its power to efficiently process the vast amount of DNA and RNA sequencing data into clinically actionable results.

Streamline your TSO 500 case analysis from FASTQ to Report, using Franklin features such as:

Automated case creation

Franklin allows for efficient integration with LIMS, EMR, and your own organization’s information system through an API, and also provides various ways to seamlessly import your data in bulk. You can easily upload batches of all raw data file formats from the BaseSpace App, as well as Amazon servers, other cloud-based sources, or your local computer directly through the platform’s UI.

Variant/Biomarker detection

Franklin has developed a dedicated and optimized variant detection pipeline for TSO 500 workflows, which is able to pick up all possible variant types on this assay. Franklin uses its own bioinformatic pipeline to identify SNPs and small insertions/deletions, combining GATK tools, DRAGEN, and dedicated indel callers, drawing on the most fitting algorithm for each step of the detection process. That way, the platform can identify artifacts and calling errors, increasing the accuracy of the overall calling results. For CNV detection, Rainbow, Franklin’s own proprietary algorithm, uses machine learning to identify amplifications and deletions.

TSO 500 allows you to analyze multiple variant types and key biomarkers in 500+ cancer-relevant genes across DNA and RNA in a single assay. For DNA, the analysis covers 523 genes (1.94 Mbp) and detects SNVs, indels, CNVs, tumor mutational burden (TMB), and microsatellite instability (MSI). If using the DNA + RNA bundle, you can also identify known and novel fusions (in 55 genes) and some splice variants (in 3 genes).

Variant interpretation

Franklin’s classification and prioritization engine leverages the power of AI to help pinpoint the relevant variants for your specific case, taking into account cancer type, updated FDA approvals and professional guidelines, recent publications, and clinical trials. Franklin presents information from more than 100 databases including prediction tools, normal population and somatic frequencies, and clinical repositories, and automatically classifies variants according to the latest AMP, ACMG, and ClinGen guidelines. The platform works as a one-stop shop for genetic evidence, presenting all the relevant information from available sources, as well as Franklin Community data, all curated by our dedicated team of cancer specialists.

TSO 500 guidelines
NTRK1, NTRK2, NTRK3 (pan-cancer) | MSI (pan-cancer) | TMB (pan-cancer)

TruSight Oncology 500 covers key guidelines for multiple tumor types, such as lung, colon, and breast cancer, as well as sarcoma, melanoma, and others, and provides information regarding a wide range of cancer-related genes involved in clinical trials. These assays are becoming increasingly popular since they allow labs to unify wet lab workflows and simplify the experimental procedures for many cancer types, instead of having dedicated experiments for each specific biomarker.

However, the amount of data resulting from such a thorough panel can be overwhelmingly complex and translate into time-consuming dry lab processing. With Franklin, you can easily analyze TSO 500 cases to reach faster and more accurate results.